A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ.
Santa-Maria CA, et al.
Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10.
Oncotarget. 2018.
PMID: 29721177
Free PMC article.